These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38295753)

  • 81. A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.
    Zhang J; Sun W; Ren C; Kong X; Yan W; Chen X
    Cancer Res; 2019 Jul; 79(14):3714-3724. PubMed ID: 31064846
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
    Liu D; Abbosh P; Keliher D; Reardon B; Miao D; Mouw K; Weiner-Taylor A; Wankowicz S; Han G; Teo MY; Cipolla C; Kim J; Iyer G; Al-Ahmadie H; Dulaimi E; Chen DYT; Alpaugh RK; Hoffman-Censits J; Garraway LA; Getz G; Carter SL; Bellmunt J; Plimack ER; Rosenberg JE; Van Allen EM
    Nat Commun; 2017 Dec; 8(1):2193. PubMed ID: 29259186
    [TBL] [Abstract][Full Text] [Related]  

  • 83. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells.
    Liu J; Bi J; Li Z; Li Z; Liu X; Kong C
    Int J Mol Med; 2018 Mar; 41(3):1765-1773. PubMed ID: 29328435
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
    Li Y; Zu X; Hu X; Wang L; He W
    Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
    [TBL] [Abstract][Full Text] [Related]  

  • 85. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
    Zheng L; Li L; Lu Y; Jiang F; Yang XA
    Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
    [TBL] [Abstract][Full Text] [Related]  

  • 86. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
    Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Lactylated Histone H3K18 as a Potential Biomarker for the Diagnosis and Predicting the Severity of Septic Shock.
    Chu X; Di C; Chang P; Li L; Feng Z; Xiao S; Yan X; Xu X; Li H; Qi R; Gong H; Zhao Y; Xiao F; Chang Z
    Front Immunol; 2021; 12():786666. PubMed ID: 35069560
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
    Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
    Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
    Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
    PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
    Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
    Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
    Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
    J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
    Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis.
    Luo G; Zhang Y; Wu Z; Zhang L; Liang C; Chen X
    Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):558-566. PubMed ID: 33720323
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 98. HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway.
    Lv J; Li K; Yu H; Han J; Zhuang J; Yu R; Cheng Y; Song Q; Bai K; Cao Q; Yang H; Yang X; Lu Q
    J Exp Clin Cancer Res; 2023 Feb; 42(1):41. PubMed ID: 36747239
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines.
    Skowron MA; Petzsch P; Hardt K; Wagner N; Beier M; Stepanow S; Drechsler M; Rieder H; Köhrer K; Niegisch G; Hoffmann MJ; Schulz WA
    Sci Rep; 2019 Oct; 9(1):14476. PubMed ID: 31597922
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Vitamin D3 sensitizes resistant human bladder cancer cells to cisplatin by regulating Sirtuin 1 gene expression.
    Di YC; Zhang ZH; Sun YP; Song J
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7656-7666. PubMed ID: 36314337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.